Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine (Q46466259)

22 December 2017

title

Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine (English)

1 reference

22 December 2017

1 reference

1

M Malik

1 reference

22 December 2017

J-O Andreas

2

J-O Andreas

1 reference

22 December 2017

K Hnatkova

3

K Hnatkova

1 reference

22 December 2017

J Hoeckendorff

4

J Hoeckendorff

1 reference

22 December 2017

W Cawello

5

W Cawello

1 reference

22 December 2017

M Middle

6

M Middle

1 reference

22 December 2017

R Horstmann

7

R Horstmann

1 reference

22 December 2017

M Braun

8

M Braun

1 reference

22 December 2017

language of work or name

English

0 references

publication date

23 July 2008

1 reference

22 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

22 December 2017

volume

84

1 reference

22 December 2017

issue

5

1 reference

22 December 2017

page(s)

595-603

1 reference

22 December 2017

Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

Oral anticoagulation for ECG tremor artefact simulating atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

Parkinson's tremor mimicking ventricular tachycardia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

Man versus machine: is there an optimal method for QT measurements in thorough QT studies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

Abnormalities of rate-corrected QT intervals in Parkinson's disease-a comparison with multiple system atrophy and progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

Ambulatory ECG and analysis of heart rate variability in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

Effects of three fluoroquinolones on QT interval in healthy adults after single doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

Assessment of noise in digital electrocardiograms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

Circadian modulation of QT rate dependence in healthy volunteers: gender and age differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

Problems of heart rate correction in assessment of drug-induced QT interval prolongation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

7 January 2021

Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

7 January 2021

Circulating microemboli in patients with myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

7 January 2021

Autonomic dysfunction in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

7 January 2021

Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

7 January 2021

Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.143

7 January 2021

Identifiers

DOI

10.1038/CLPT.2008.143

1 reference

22 December 2017

PubMed ID

18650802

1 reference

22 December 2017